Search Videos and More
News
Exploring How CAR T-Cell Therapy May Help More Patients
CAR T-cell therapy burst onto the scene as a revolutionary treatment for cancer patients in 2015, when it was introduced in clinical trials primarily for patients with lymphoma and leukemia. Since then, it has transformed the course of disease, primarily for blood cancer patients, with many clinical trials now exploring the approach for solid tumor patients. Through this highly tailored form of immune effector cell (IEC) therapy, typically a patient's own immune cells — known as T cells — are genetically re-engineered to identify and kill cancer cells.
News
Dana-Farber Research Publication 01.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Course
Topics in Gastrointestinal Oncology
This course is designed to give medical oncologists, surgeons, radiation oncologists, gastroenterologists, primary care physicians, nurses, and other interested clinicians updated information regarding the management of gastrointestinal cancers.
News
Dana-Farber Research Publication 12.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Publication 12.1.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
2023 ASH Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.
Symposium
2023 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2023 San Antonio Breast Cancer Symposium.
News
2023 Updates in Neuro-Oncology
Please join us on Zoom for a free symposium on the latest advances in neuro-oncology. Through lecture and discussion, Harvard Medical School faculty will consider how to apply recent clinical research advances to improve the care and outcomes of patients with brain tumors.
News
Dana-Farber Research Publication 11.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
2023 ESMO Congress Research Highlights
Learn more about lung, kidney, and neuroendocrine tumor cancer studies led by Dana-Farber presented at ESMO Congress 2023.
News
Dana-Farber Research Publication 11.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Document
Treatment Guideline: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.